Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase, is approved by the US Food and Drug Administration (FDA) as both a first- and a second-line treatment for CLL. Two new studies of ibrutinib, summarized here, provide important new information on cost and healthcare resource utilization (HRU), as well as confirmatory data on clinical benefit, relative to other therapies in patients with CLL in the US general population and among US veterans of the armed services, a relatively understudied group.